25 XP   0   0   10

Invex Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Invex Therapeutics Ltd together

PenkeI guess you are interested in Invex Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Invex Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Invex Therapeutics Ltd

I send you an email if I find something interesting about Invex Therapeutics Ltd.

Quick analysis of Invex Therapeutics Ltd (30 sec.)










What can you expect buying and holding a share of Invex Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.07
Expected worth in 1 year
A$-0.27
How sure are you?
36.8%

+ What do you gain per year?

Total Gains per Share
A$-0.34
Return On Investment
-405.7%

For what price can you sell your share?

Current Price per Share
A$0.09
Expected price per share
A$0.078 - A$0.089
How sure are you?
50%

1. Valuation of Invex Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.09

2. Growth of Invex Therapeutics Ltd (5 min.)




Is Invex Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$3.4m$17.3m-$6.9m-67.1%

How much money is Invex Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$1.7m-$1.4m-$262.9k-15.2%
Net Profit Margin-849.9%-1,483.6%--

How much money comes from the company's main activities?

3. Financial Health of Invex Therapeutics Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#793 / 1031

Most Revenue
#623 / 1031

Most Profit
#301 / 1031

Most Efficient
#806 / 1031

What can you expect buying and holding a share of Invex Therapeutics Ltd? (5 min.)

Welcome investor! Invex Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Invex Therapeutics Ltd.

What can you expect buying and holding a share of Invex Therapeutics Ltd?

First you should know what it really means to hold a share of Invex Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Invex Therapeutics Ltd is A$0.085. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Invex Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Invex Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.07. Based on the TTM, the Book Value Change Per Share is A$-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Invex Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-21.6%-0.02-27.1%-0.02-19.8%-0.01-12.3%-0.01-12.3%
Usd Book Value Change Per Share-0.14-162.7%-0.06-66.2%0.00-2.1%0.002.8%0.002.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.14-162.7%-0.06-66.2%0.00-2.1%0.002.8%0.002.8%
Usd Price Per Share0.05-0.15-0.37-0.38-0.38-
Price to Earnings Ratio-0.72--1.94--7.39--14.53--14.53-
Price-to-Total Gains Ratio-0.38--369,482.63-7,802.13-1,204,863.80-1,204,863.80-
Price to Book Ratio1.15-1.13-1.67-2.27-2.27-
Price-to-Total Gains Ratio-0.38--369,482.63-7,802.13-1,204,863.80-1,204,863.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0554455
Number of shares18035
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.00
Usd Total Gains Per Share-0.060.00
Gains per Quarter (18035 shares)-1,014.3043.63
Gains per Year (18035 shares)-4,057.22174.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4057-40670175165
20-8114-81240349340
30-12172-121810524515
40-16229-162380698690
50-20286-202950873865
60-24343-24352010471040
70-28401-28409012221215
80-32458-32466013961390
90-36515-36523015711565
100-40572-40580017451740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%0.011.00.00.0%0.019.00.00.0%0.019.00.00.0%0.019.00.00.0%
Book Value Change Per Share0.03.00.00.0%3.06.02.027.3%7.08.04.036.8%7.08.04.036.8%7.08.04.036.8%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share0.03.00.00.0%3.06.02.027.3%7.08.04.036.8%7.08.04.036.8%7.08.04.036.8%

Fundamentals of Invex Therapeutics Ltd

About Invex Therapeutics Ltd

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.

Fundamental data was last updated by Penke on 2024-03-10 08:51:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Invex Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Invex Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Invex Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-849.9%+849.9%
TTM-849.9%YOY-1,483.6%+633.7%
TTM-849.9%5Y-10,110.5%+9,260.6%
5Y-10,110.5%10Y-10,110.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM-849.9%-202.3%-647.6%
YOY-1,483.6%-263.0%-1,220.6%
5Y-10,110.5%-452.4%-9,658.1%
10Y-10,110.5%-589.0%-9,521.5%
1.1.2. Return on Assets

Shows how efficient Invex Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • -33.6% Return on Assets means that Invex Therapeutics Ltd generated $-0.34 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Invex Therapeutics Ltd:

  • The MRQ is -33.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.6%TTM-19.8%-13.9%
TTM-19.8%YOY-8.3%-11.5%
TTM-19.8%5Y-7.4%-12.4%
5Y-7.4%10Y-7.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.6%-12.5%-21.1%
TTM-19.8%-12.2%-7.6%
YOY-8.3%-11.2%+2.9%
5Y-7.4%-13.3%+5.9%
10Y-7.4%-14.6%+7.2%
1.1.3. Return on Equity

Shows how efficient Invex Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • -39.9% Return on Equity means Invex Therapeutics Ltd generated $-0.40 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Invex Therapeutics Ltd:

  • The MRQ is -39.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.9%TTM-22.9%-17.0%
TTM-22.9%YOY-8.8%-14.0%
TTM-22.9%5Y-8.1%-14.8%
5Y-8.1%10Y-8.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.9%-16.0%-23.9%
TTM-22.9%-15.8%-7.1%
YOY-8.8%-13.9%+5.1%
5Y-8.1%-18.2%+10.1%
10Y-8.1%-19.1%+11.0%

1.2. Operating Efficiency of Invex Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Invex Therapeutics Ltd is operating .

  • Measures how much profit Invex Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Invex Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,200.4%+1,200.4%
TTM-1,200.4%YOY-855.3%-345.1%
TTM-1,200.4%5Y-5,739.0%+4,538.7%
5Y-5,739.0%10Y-5,739.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-1,200.4%-208.5%-991.9%
YOY-855.3%-280.2%-575.1%
5Y-5,739.0%-459.9%-5,279.1%
10Y-5,739.0%-596.9%-5,142.1%
1.2.2. Operating Ratio

Measures how efficient Invex Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Invex Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.483-10.483
TTM10.483YOY1.508+8.975
TTM10.4835Y53.590-43.108
5Y53.59010Y53.5900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM10.4833.181+7.302
YOY1.5083.609-2.101
5Y53.5905.554+48.036
10Y53.5907.396+46.194

1.3. Liquidity of Invex Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Invex Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.38 means the company has $6.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Invex Therapeutics Ltd:

  • The MRQ is 6.379. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.795. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.379TTM11.795-5.416
TTM11.795YOY25.827-14.032
TTM11.7955Y26.439-14.645
5Y26.43910Y26.4390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3793.987+2.392
TTM11.7954.440+7.355
YOY25.8275.569+20.258
5Y26.4396.158+20.281
10Y26.4396.492+19.947
1.3.2. Quick Ratio

Measures if Invex Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 6.38 means the company can pay off $6.38 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Invex Therapeutics Ltd:

  • The MRQ is 6.379. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.724. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.379TTM11.724-5.345
TTM11.724YOY25.827-14.103
TTM11.7245Y16.205-4.481
5Y16.20510Y16.2050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3793.653+2.726
TTM11.7244.158+7.566
YOY25.8275.515+20.312
5Y16.2056.012+10.193
10Y16.2056.206+9.999

1.4. Solvency of Invex Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Invex Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Invex Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Invex Therapeutics Ltd assets are financed with 15.7% credit (debt) and the remaining percentage (100% - 15.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Invex Therapeutics Ltd:

  • The MRQ is 0.157. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.098. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.157TTM0.098+0.059
TTM0.098YOY0.039+0.059
TTM0.0985Y0.053+0.046
5Y0.05310Y0.0530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1570.336-0.179
TTM0.0980.330-0.232
YOY0.0390.267-0.228
5Y0.0530.367-0.314
10Y0.0530.378-0.325
1.4.2. Debt to Equity Ratio

Measures if Invex Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.6% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Invex Therapeutics Ltd:

  • The MRQ is 0.186. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.114. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.186TTM0.114+0.071
TTM0.114YOY0.042+0.072
TTM0.1145Y0.057+0.057
5Y0.05710Y0.0570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1860.376-0.190
TTM0.1140.398-0.284
YOY0.0420.334-0.292
5Y0.0570.431-0.374
10Y0.0570.476-0.419

2. Market Valuation of Invex Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Invex Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Invex Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -0.72 means the investor is paying $-0.72 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Invex Therapeutics Ltd:

  • The EOD is -0.756. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.720. Based on the earnings, the company is expensive. -2
  • The TTM is -1.942. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.756MRQ-0.720-0.036
MRQ-0.720TTM-1.942+1.221
TTM-1.942YOY-7.394+5.452
TTM-1.9425Y-14.529+12.587
5Y-14.52910Y-14.5290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.756-2.697+1.941
MRQ-0.720-2.422+1.702
TTM-1.942-2.709+0.767
YOY-7.394-4.116-3.278
5Y-14.529-6.257-8.272
10Y-14.529-6.478-8.051
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Invex Therapeutics Ltd:

  • The EOD is -0.689. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.657. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.466. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.689MRQ-0.657-0.032
MRQ-0.657TTM-2.466+1.810
TTM-2.466YOY-2.105-0.361
TTM-2.4665Y-10.330+7.864
5Y-10.33010Y-10.3300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.689-3.344+2.655
MRQ-0.657-2.939+2.282
TTM-2.466-3.486+1.020
YOY-2.105-5.592+3.487
5Y-10.330-8.464-1.866
10Y-10.330-8.872-1.458
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Invex Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.15 means the investor is paying $1.15 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Invex Therapeutics Ltd:

  • The EOD is 1.206. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.149. Based on the equity, the company is underpriced. +1
  • The TTM is 1.127. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.206MRQ1.149+0.057
MRQ1.149TTM1.127+0.023
TTM1.127YOY1.669-0.543
TTM1.1275Y2.270-1.143
5Y2.27010Y2.2700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2062.198-0.992
MRQ1.1492.042-0.893
TTM1.1272.121-0.994
YOY1.6692.907-1.238
5Y2.2703.682-1.412
10Y2.2704.114-1.844
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Invex Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Invex Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.212-0.086-59%-0.003-99%0.004-5817%0.004-5817%
Book Value Per Share--0.0700.212-67%0.339-79%0.265-73%0.265-73%
Current Ratio--6.37911.795-46%25.827-75%26.439-76%26.439-76%
Debt To Asset Ratio--0.1570.098+60%0.039+297%0.053+198%0.053+198%
Debt To Equity Ratio--0.1860.114+62%0.042+341%0.057+224%0.057+224%
Dividend Per Share----0%-0%-0%-0%
Eps---0.028-0.035+26%-0.026-8%-0.016-43%-0.016-43%
Free Cash Flow Per Share---0.031-0.030-3%-0.039+27%-0.021-32%-0.021-32%
Free Cash Flow To Equity Per Share---0.217-0.092-58%-0.039-82%-0.044-80%-0.044-80%
Gross Profit Margin--1.0001.048-5%1.010-1%1.010-1%1.010-1%
Market Cap6388073.000+5%6087461.68817811455.096-66%44264405.695-86%46916140.908-87%46916140.908-87%
Net Profit Margin----8.4990%-14.8360%-101.1050%-101.1050%
Operating Margin----12.0040%-8.5530%-57.3900%-57.3900%
Operating Ratio---10.483-100%1.508-100%53.590-100%53.590-100%
Pb Ratio1.206+5%1.1491.127+2%1.669-31%2.270-49%2.270-49%
Pe Ratio-0.756-5%-0.720-1.942+170%-7.394+926%-14.529+1917%-14.529+1917%
Price Per Share0.085+5%0.0810.237-66%0.560-86%0.579-86%0.579-86%
Price To Free Cash Flow Ratio-0.689-5%-0.657-2.466+276%-2.105+221%-10.330+1473%-10.330+1473%
Price To Total Gains Ratio-0.401-5%-0.382-369482.628+96722084%7802.132-100%1204863.804-100%1204863.804-100%
Quick Ratio--6.37911.724-46%25.827-75%16.205-61%16.205-61%
Return On Assets---0.336-0.198-41%-0.083-75%-0.074-78%-0.074-78%
Return On Equity---0.399-0.229-43%-0.088-78%-0.081-80%-0.081-80%
Total Gains Per Share---0.212-0.086-59%-0.003-99%0.004-5817%0.004-5817%
Usd Book Value--3454477.73710384337.250-67%17356361.219-80%13978258.028-75%13978258.028-75%
Usd Book Value Change Per Share---0.138-0.056-59%-0.002-99%0.002-5817%0.002-5817%
Usd Book Value Per Share--0.0460.138-67%0.221-79%0.173-73%0.173-73%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.018-0.023+26%-0.017-8%-0.010-43%-0.010-43%
Usd Free Cash Flow---1511550.655-1467200.126-3%-957764.915-37%-488344.910-68%-488344.910-68%
Usd Free Cash Flow Per Share---0.020-0.020-3%-0.025+27%-0.014-32%-0.014-32%
Usd Free Cash Flow To Equity Per Share---0.142-0.060-58%-0.025-82%-0.029-80%-0.029-80%
Usd Market Cap4166940.018+5%3970851.25911618412.159-66%28873671.835-86%30603398.714-87%30603398.714-87%
Usd Price Per Share0.055+5%0.0530.155-66%0.365-86%0.378-86%0.378-86%
Usd Profit---1378113.558-1731934.993+26%-1468984.003+7%-917475.090-33%-917475.090-33%
Usd Revenue---99820.599-100%136076.303-100%64771.433-100%64771.433-100%
Usd Total Gains Per Share---0.138-0.056-59%-0.002-99%0.002-5817%0.002-5817%
 EOD+5 -3MRQTTM+6 -26YOY+6 -265Y+3 -2910Y+3 -29

4.2. Fundamental Score

Let's check the fundamental score of Invex Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.756
Price to Book Ratio (EOD)Between0-11.206
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.379
Current Ratio (MRQ)Greater than16.379
Debt to Asset Ratio (MRQ)Less than10.157
Debt to Equity Ratio (MRQ)Less than10.186
Return on Equity (MRQ)Greater than0.15-0.399
Return on Assets (MRQ)Greater than0.05-0.336
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Invex Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.177
Ma 20Greater thanMa 500.084
Ma 50Greater thanMa 1000.085
Ma 100Greater thanMa 2000.120
OpenGreater thanClose0.084
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets6,280
Total Liabilities985
Total Stockholder Equity5,296
 As reported
Total Liabilities 985
Total Stockholder Equity+ 5,296
Total Assets = 6,280

Assets

Total Assets6,280
Total Current Assets6,280
Long-term Assets-
Total Current Assets
Cash And Cash Equivalents 6,152
Net Receivables 129
Total Current Assets  (as reported)6,280
Total Current Assets  (calculated)6,280
+/- 0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities985
Long-term Liabilities-
Total Stockholder Equity5,296
Total Current Liabilities
Accounts payable 358
Other Current Liabilities 627
Total Current Liabilities  (as reported)985
Total Current Liabilities  (calculated)985
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock22,412
Retained Earnings -19,692
Accumulated Other Comprehensive Income 2,576
Total Stockholder Equity (as reported)5,296
Total Stockholder Equity (calculated)5,296
+/-0
Other
Cash and Short Term Investments 6,152
Common Stock Shares Outstanding 75,154
Liabilities and Stockholders Equity 6,280
Net Debt -6,152



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-12-312023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
638
12,374
10,996
10,996
0
26,417
0
33,655
0
32,737
0
31,511
29,485
29,485
25,897
25,897
22,804
22,804
6,280
6,28022,80422,80425,89725,89729,48529,48531,511032,737033,655026,417010,99610,99612,374638
   > Total Current Assets 
520
12,256
10,878
10,878
26,417
26,417
33,655
33,655
32,737
32,737
31,511
31,511
29,485
29,485
25,897
25,897
22,804
22,804
6,280
6,28022,80422,80425,89725,89729,48529,48531,51131,51132,73732,73733,65533,65526,41726,41710,87810,87812,256520
       Cash And Cash Equivalents 
499
12,170
10,843
10,843
0
26,300
0
33,582
0
32,716
0
31,366
29,339
29,339
25,424
25,424
22,470
22,470
6,152
6,15222,47022,47025,42425,42429,33929,33931,366032,716033,582026,300010,84310,84312,170499
       Net Receivables 
3
86
34
34
117
117
73
73
21
21
145
145
146
146
473
473
0
334
129
1293340473473146146145145212173731171173434863
   > Long-term Assets 0000000000000000000
       Intangible Assets 
118
118
118
118
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000118118118118
> Total Liabilities 
40
935
535
535
0
2,015
0
634
0
659
0
966
1,004
1,004
1,162
1,162
1,572
1,572
985
9851,5721,5721,1621,1621,0041,0049660659063402,015053553593540
   > Total Current Liabilities 
40
935
535
535
2,015
2,015
634
634
659
659
966
966
1,004
1,004
1,162
1,162
1,572
1,572
985
9851,5721,5721,1621,1621,0041,0049669666596596346342,0152,01553553593540
       Accounts payable 
40
935
14
14
30
30
21
21
11
11
311
311
139
139
437
437
1,143
1,143
358
3581,1431,143437437139139311311111121213030141493540
       Other Current Liabilities 
0
0
0
0
1,302
1,985
0
0
0
647
0
0
865
865
725
725
429
429
627
627429429725725865865006470001,9851,3020000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
139
139
0
0
0
0
0
00000139139000000000000
> Total Stockholder Equity
598
11,438
10,460
10,460
0
24,402
0
33,020
0
32,079
0
30,545
28,481
28,481
22,736
24,735
18,834
21,231
5,296
5,29621,23118,83424,73522,73628,48128,48130,545032,079033,020024,402010,46010,46011,438598
   Common Stock
610
11,670
11,670
11,670
27,017
27,017
36,413
36,413
36,413
36,413
36,413
36,413
36,413
36,413
36,413
36,413
36,413
36,413
22,412
22,41236,41336,41336,41336,41336,41336,41336,41336,41336,41336,41336,41336,41327,01727,01711,67011,67011,670610
   Retained Earnings -19,692-17,579-17,579-13,678-13,678-9,829-9,829-7,672-7,672-5,876-5,876-4,648-4,648-3,592-3,592-1,343-1,343-232-11
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
-1
0
133
133
977
977
1,255
1,255
1,542
1,542
1,804
1,804
1,897
1,897
-22,736
-22,736
-18,834
-18,834
0
0-18,834-18,834-22,736-22,7361,8971,8971,8041,8041,5421,5421,2551,2559779771331330-1



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue459
Cost of Revenue--
Gross Profit459459
 
Operating Income (+$)
Gross Profit459
Operating Expense-8,979
Operating Income-8,547-8,520
 
Operating Expense (+$)
Research Development7,400
Selling General Administrative1,286
Selling And Marketing Expenses-
Operating Expense8,9798,687
 
Net Interest Income (+$)
Interest Income797
Interest Expense--
Other Finance Cost-0
Net Interest Income797
 
Pretax Income (+$)
Operating Income-8,547
Net Interest Income797
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-7,750-8,979
EBIT - interestExpense = -17,526
-17,094
-7,750
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-17,526-7,750
Earnings Before Interest and Taxes (EBITDA)-8,979
 
After tax Income (+$)
Income Before Tax-7,750
Tax Provision-0
Net Income From Continuing Ops-7,750-7,750
Net Income-7,750
Net Income Applicable To Common Shares-7,750
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-9,006
Total Other Income/Expenses Net432-797
 

Technical Analysis of Invex Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Invex Therapeutics Ltd. The general trend of Invex Therapeutics Ltd is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Invex Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Invex Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.089 < 0.089 < 0.089.

The bearish price targets are: 0.078 > 0.078 > 0.078.

Tweet this
Invex Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Invex Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Invex Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Invex Therapeutics Ltd. The current macd is -0.00037808.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Invex Therapeutics Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Invex Therapeutics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Invex Therapeutics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Invex Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartInvex Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Invex Therapeutics Ltd. The current adx is 12.10.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Invex Therapeutics Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Invex Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Invex Therapeutics Ltd. The current sar is 0.12278959.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Invex Therapeutics Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Invex Therapeutics Ltd. The current rsi is 48.18. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Invex Therapeutics Ltd Daily Relative Strength Index (RSI) ChartInvex Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Invex Therapeutics Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Invex Therapeutics Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Invex Therapeutics Ltd Daily Stochastic Oscillator ChartInvex Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Invex Therapeutics Ltd. The current cci is 10.10.

Invex Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartInvex Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Invex Therapeutics Ltd. The current cmo is -3.84405831.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Invex Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartInvex Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Invex Therapeutics Ltd. The current willr is -44.44444444.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Invex Therapeutics Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Invex Therapeutics Ltd Daily Williams %R ChartInvex Therapeutics Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Invex Therapeutics Ltd.

Invex Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Invex Therapeutics Ltd. The current atr is 0.0028188.

Invex Therapeutics Ltd Daily Average True Range (ATR) ChartInvex Therapeutics Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Invex Therapeutics Ltd. The current obv is -8,469,351.

Invex Therapeutics Ltd Daily On-Balance Volume (OBV) ChartInvex Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Invex Therapeutics Ltd. The current mfi is 0.55916179.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Invex Therapeutics Ltd Daily Money Flow Index (MFI) ChartInvex Therapeutics Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Invex Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Invex Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Invex Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.177
Ma 20Greater thanMa 500.084
Ma 50Greater thanMa 1000.085
Ma 100Greater thanMa 2000.120
OpenGreater thanClose0.084
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Invex Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Invex Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Invex Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Invex Therapeutics Ltd

I send you an email if I find something interesting about Invex Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Invex Therapeutics Ltd.

Receive notifications about Invex Therapeutics Ltd in your mailbox!